Louise Frederika Kooij Sells 2,647 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 2,647 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $33.25, for a total transaction of $88,012.75. Following the sale, the chief accounting officer owned 12,353 shares of the company’s stock, valued at approximately $410,737.25. This represents a 17.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Louise Frederika Kooij also recently made the following trade(s):

• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS traded up $1.43 on Wednesday, reaching $35.45. The stock had a trading volume of 759,782 shares, compared to its average volume of 845,920. The company has a market cap of $4.02 billion, a P/E ratio of -17.29 and a beta of 0.07. The firm has a fifty day moving average of $36.87 and a two-hundred day moving average of $29.80. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million. Research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on NAMS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Citigroup lifted their price objective on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Leerink Partners reiterated an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday. Royal Bank Of Canada raised their price target on NewAmsterdam Pharma from $39.00 to $44.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Needham & Company LLC boosted their price target on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.73.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently modified their holdings of the business. Capital World Investors lifted its position in shares of NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after buying an additional 1,434,986 shares during the last quarter. Jennison Associates LLC raised its stake in NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after acquiring an additional 1,252,451 shares in the last quarter. Duquesne Family Office LLC lifted its holdings in shares of NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after acquiring an additional 1,091,525 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after purchasing an additional 1,062,359 shares in the last quarter. Finally, Maverick Capital Ltd. increased its position in NewAmsterdam Pharma by 178.8% during the 2nd quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock worth $27,742,000 after purchasing an additional 982,405 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.